Summary
Identifying genes linked to extreme phenotypes in humans has the potential to highlight new biological processes fundamental for human development. Here we report the identification of homozygous loss of function variants in the primate-specific gene ZNF808 as a cause of pancreatic agenesis. ZNF808 is a member of the KRAB zinc finger protein (KZFPs) family, a large and rapidly evolving group of epigenetic silencers that target transposable elements. We show that loss of ZNF808 in vitro results in aberrant activation of many transposable elements it normally represses during early pancreas development. This results in inappropriate specification of cell fate with induction of genes associated with liver endoderm and a loss of pancreatic identity. We show that ZNF808 and its transposable element targets play a critical role in cell fate specification during human pancreatic development. This is the first report of loss of a primate-specific gene causing a congenital developmental disease and highlights the essential role of ZNF808 for pancreatic development in humans.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
EDF is a Diabetes UK RD Lawrence Fellow (19/005971) and has been the recipient of an EASD Rising Star fellowship during this study. ATH and SE were the recipients of a Wellcome Trust Senior Investigator award (grant WT098395/Z/12/Z) during this study, and ATH is employed as a core member of staff within the National Institute for Health Research funded Exeter Clinical Research Facility and is an NIHR Emeritus Senior Investigator. SEF and MI have Sir Henry Dale Fellowships jointly funded by the Wellcome Trust and the Royal Society (grant 105636/Z/14/Z and 206688/Z/17/Z, respectively). NO has a lectureship funded by a Research England Expanding Excellence in England (E3) award. Most of the experimental studies were funded by the Academy of Finland Center of Excellence MetaStem (grant 312437). The Novo Nordisk Foundation and the Sigrid Juselius Foundation. HM is a member of the Doctoral Program in Integrative Life Science at University of Helsinki. AT Doctoral studies were funded by the Foundation for Education and European Culture (IPEP) in Greece and by the Cambridge Trust. DB received funding from a European Molecular Biology Organization long term fellowship (ALTF 295/2019).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethical approval for the patient DNA analysis in this study was part of the Genetic Beta Cell Research Bank based in Exeter this was approved by Wales Research Ethics Committee 5 on 20/05/13 (REC ref 12/WA/0225) and renewed on 26/10/2017 (REC ref 17/WA/0327)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data will be made available on publication in a peer reviewed publication. All disease-causing variants identified by next generation sequencing will be uploaded onto the DECIPHER database (https://decipher.sanger.ac.uk/). All variants identified through genome sequencing will be submitted as a .vcf file with allele frequencies to the EMBL-EBI European Genome-Phenome Archive (EGA) (https://www.ebi.ac.uk/ega/home).
All epigenomic and transcriptomic data from in vitro pancreatic differentiation will be deposited in NCBI Gene Expression Omnibus (GEO, https://www.ncbi.nlm.nih.gov/geo/).
